% Expired Patents = 20.0

CIPO Patents = 1

EPO Patents = 3

Forward Citations = 45

Loading Chart...

6 inventors (with patents filed for the assignee):

Thomas Kirkegaard Jensen (4 out of 14 patents)

Marja Helena Jaattela (3 out of 8 patents)

Anders Mørkeberg Hinsby (1 out of 5 patents)

4. Linda Greensmith (1 out of 1 patent)

5. Geoffrey Burnstock (1 out of 1 patent)

6. Rudolf Urbanics (1 out of 1 patent)

5 patents: Sort by Forward Citations

1. 9884058 - Use of Hsp70 as a regulator of enzymatic activity (2018-02-06),

2. 9662375 - Methods for increasing intracellular activity of Hsp70 (2017-05-30),

3. 9289472 - Use of HSP70 as a regulator of enzymatic activity (2016-03-22),

4. 8962604 - Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases (2015-02-24),

5. 8540985 - Use of Hsp70 as a regulator of enzymatic activity (2013-09-24),

Company Overview

Orphazyme Aps is a biopharmaceutical company dedicated to developing novel therapies for patients with rare neurological diseases. Their lead candidate, Arimoclomol, is being investigated for the treatment of neurodegenerative disorders such as Niemann-Pick disease type C and sporadic Inclusion Body Myositis. Orphazyme's mission is to bring hope to patients and their families by advancing innovative treatments that address unmet medical needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

5 Patents

#56 in Copenhagen

#471 in Denmark

Copenhagen, Denmark

Orphazyme Aps

Forward Citations = 45

6 inventors:

Thomas Kirkegaard Jensen (4 out of 14 patents)

Marja Helena Jaattela (3 out of 8 patents)

Anders Mørkeberg Hinsby (1 out of 5 patents)

4. Linda Greensmith (1 out of 1 patent)

5. Geoffrey Burnstock (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Orphazyme Aps. Retrieved from https://idiyas.com/company/orphazyme-aps

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]